Altreno, Atralin, Avita, Renova, Retin-a, Retin-a Micro, Retin-a-micro, Vesanoid (tretinoin) is a small molecule pharmaceutical. Tretinoin was first approved as Altreno on 1982-01-01. It is used to treat acne vulgaris, facial dermatoses, hyperpigmentation, and promyelocytic leukemia acute in the USA. The pharmaceutical is active against retinoic acid receptor gamma, retinoic acid receptor alpha, and retinoic acid receptor beta. In addition, it is known to target Nuclear receptor ROR-beta, nuclear receptor subfamily 2 group C member 2, peroxisome proliferator-activated receptor delta, and nuclear receptor subfamily 2 group E member 1. Tretinoin cream's patent is valid until 2038-08-22 (FDA).
|Trade Name||Altreno, Atralin, Avita, Renova, Retin-a, Retin-a Micro, Retin-a-micro, Vesanoid|
|Indication||acne vulgaris, facial dermatoses, hyperpigmentation, promyelocytic leukemia acute|
|Drug Class||Retinol derivatives|